Physician profile
Mark A Nelson
NPI 1669959607
$3,637.41
in general payments reported to CMS, 2019-2025
23 companies · $706 in 2025
The $706 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $150 · 2021: $717 · 2022: $557 · 2023: $803 · 2024: $705 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,213.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,432.73 | 2021-2025 | Precision 1, Tryptyr, Rocklatan |
| Tarsus Pharmaceuticals, INC. | $379.08 | 2024-2025 | Xdemvy |
| Coopervision INC. | $336.80 | 2020-2024 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $240.78 | 2022-2025 | Infuse, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $188.68 | 2021-2025 | Cequa |
| Johnson & Johnson Vision Care, INC. | $165.69 | 2022-2024 | |
| Oyster Point Pharma, INC. | $136.15 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Abbvie INC. | $119.84 | 2022-2023 | |
| Horizon Therapeutics Plc | $116.05 | 2023 | Tepezza |
| Dompe US, INC. | $105.85 | 2022-2025 | Oxervate |
| Allergan, INC. | $86.57 | 2021 | |
| Kala Pharmaceuticals, INC. | $55.27 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $47.08 | 2021 | |
| Thea Pharma INC. | $39.37 | 2023-2025 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $28.38 | 2020-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $26.19 | 2025 | Koselugo |
| Amgen INC. | $24.71 | 2025 | Tepezza |
| Lkc Technologies, INC. | $23.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $21.23 | 2022 | |
| Sight Sciences, INC. | $20.23 | 2021 | |
| Eyevance Pharmaceuticals LLC | $15.65 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.38 | 2022 | |
| Biotissue Holdings INC. | $13.70 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.